Table 1.
Patient characteristics for the pulmonary arterial hypertension cohort.
| Population (n = 223) | |
|---|---|
| Demographics | |
| Age | 48.1 (14.1) |
| Male | 49 (22.0%) |
| White race | 124 (55.6%) |
| Etiology | |
| Idiopathic | 90 (40.4%) |
| Connective tissue disease | 55 (24.7%) |
| IV drug abuse | 7 (3.2%) |
| Simple repaired congenital | 4 (1.8%) |
| Comorbidity | |
| Lung disease | 17 (7.6%) |
| Advanced liver disease | 14 (6.3%) |
| Medications | |
| Treatment naive | 145 (65%) |
| Biological markers | |
| NT‐proBNP (pg/mL) | |
| <300 | 59 (26.5%) |
| 300−1100 | 55 (24.7%) |
| ≥ 1100 | 109 (48.9%) |
| GFR by CKDepi (mL/min/1.73 m2) | 55.0 (22.1) |
| Sodium (mM) | 138 (3.4) |
| Hemoglobin (g/dL) | 13.3 (2.3) |
| Bilirubin (mg/dL) | 0.97 (1.0) |
| RHC parameters | |
| mPAP (mmHg) | 51.6 (13.8) |
| RAP (mmHg) | 9.3 (5.2) |
| PAWP (mmHg) | 11.1 (4.8) |
| CI (L/min/m2) | 2.0 (0.6) |
| PVRi (WU/m2) | 22.5 (6.3) |
| NYHA status | |
| 1 | 6 (2.7%) |
| 2 | 52 (23.3%) |
| 3 | 80 (35.9%) |
| 4 | 78 (35.0%) |
| Reveal lite 2.0 score | |
| ≤5 | 53 (23.8%) |
| 6−7 | 42 (18.8%) |
| ≥8 | 127 (57%) |
| Outcomes | |
| Death or transplant within 5 years | 78 (35%) |
Abbreviations: GFR, glomerular filtration rate; mPAP, mean pulmonary artery pressure; NYHA, New York Heart Association; PAWP, pulmonary capillary wedge pressure; PVRi, pulmonary vascular resistance index; RAP, right atrial pressure; RHC, right heart catheterization.